TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50
2 MARKET SEGMENTATION 54
2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 69
4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71
5 EPIDEMIOLOGY 72
6 INDUSTRIAL INSIGHTS 73
7 REGULATORY FRAMEWORK 74
8 MARKET OVERVIEW 76
8.1 DRIVERS 78
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83
9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84
9.1 OVERVIEW 85
9.2 IMAGING 88
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
9.2.1.2 ANALOG MAMMOGRAPHY 90
9.2.1.3 3D BREAST TOMOSYNTHESIS 90
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
9.2.1.7 OTHERS 90
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
9.2.2.1 OPTICAL IMAGING 91
9.2.2.2 BREAST ULTRASOUND 91
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
9.2.2.5 BREAST THERMOGRAPHY 92
9.2.3 BIOPSY 92
9.2.3.1 SURGICAL BIOPSY 93
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
9.2.3.3 CORE NEEDLE BIOPSY 93
9.2.3.4 IMAGE-GUIDED BIOPSY 93
9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
9.2.4 GENOMIC TEST 94
9.2.4.1 MOLECULAR TESTING 95
9.2.4.1.1 PD-L1 96
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
9.2.4.1.3 NTRK GENE FUSIONS 96
9.2.4.1.4 PI3KCA GENE MUTATION 96
9.2.4.2 MAMMAPRINT 96
9.2.4.3 ONCOTYPE DX 96
9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98
10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99
10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105
11 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106
11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112
12 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114
12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119
13 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120
13.1 MIDDLE EAST AND AFRICA 121
13.1.1 EGYPT 130
13.1.2 SOUTH AFRICA 136
13.1.3 ISRAEL 142
13.1.4 SAUDI ARABIA 148
13.1.5 UAE 154
13.1.6 REST OF MIDDLE EAST AND AFRICA 160
14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 161
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 161
15 SWOT ANALYSIS 162
16 COMPANY PROFILE 163
16.1 HOLOGIC, INC. 163
16.1.1 COMPANY SNAPSHOT 163
16.1.2 REVENUE ANALYSIS 163
16.1.3 COMPANY SHARE ANALYSIS 164
16.1.4 PRODUCT PORTFOLIO 164
16.1.5 RECENT DEVELOPMENTS 165
16.2 SIEMENS HEALTHCARE GMBH 166
16.2.1 COMPANY SNAPSHOT 166
16.2.2 REVENUE ANALYSIS 167
16.2.3 COMPANY SHARE ANALYSIS 167
16.2.4 PRODUCT PORTFOLIO 168
16.2.5 RECENT DEVELOPMENTS 168
16.3 F. HOFFMANN- LA ROCHE LTD 169
16.3.1 COMPANY SNAPSHOT 169
16.3.2 REVENUE ANALYSIS 169
16.3.3 COMPANY SHARE ANALYSIS 170
16.3.4 PRODUCT PORTFOLIO 170
16.3.5 RECENT DEVELOPMENTS 171
16.4 KONINKLIJKE PHILIPS N.V. 172
16.4.1 COMPANY SNAPSHOT 172
16.4.2 REVENUE ANALYSIS 172
16.4.3 COMPANY SHARE ANALYSIS 173
16.4.4 PRODUCT PORTFOLIO 173
16.4.5 RECENT DEVELOPMENTS 174
16.5 ABBOTT 175
16.5.1 COMPANY SNAPSHOT 175
16.5.2 REVENUE ANALYSIS 175
16.5.3 COMPANY SHARE ANALYSIS 176
16.5.4 PRODUCT PORTFOLIO 176
16.5.5 RECENT DEVELOPMENTS 176
16.6 ABACUS ALS 177
16.6.1 COMPANY SNAPSHOT 177
16.6.2 PRODUCT PORTFOLIO 177
16.6.3 RECENT DEVELOPMENTS 177
16.7 BD 178
16.7.1 COMPANY SNAPSHOT 178
16.7.2 REVENUE ANALYSIS 178
16.7.3 COMPANY SHARE ANALYSIS 179
16.7.4 PRODUCT PORTFOLIO 179
16.7.5 RECENT DEVELOPMENTS 179
16.8 BIOCEPT, INC. 180
16.8.1 COMPANY SNAPSHOT 180
16.8.2 REVENUE ANALYSIS 180
16.8.3 PRODUCT PORTFOLIO 181
16.8.4 RECENT DEVELOPMENTS 181
16.9 BIOMRIEUX 182
16.9.1 COMPANY SNAPSHOT 182
16.9.2 REVENUE ANALYSIS 182
16.9.3 PRODUCT PORTFOLIO 183
16.9.4 RECENT DEVELOPMENTS 183
16.10 BIO-RAD LABORATORIES, INC. 184
16.10.1 COMPANY SNAPSHOT 184
16.10.2 REVENUE ANALYSIS 184
16.10.3 PRODUCT PORTFOLIO 185
16.10.4 RECENT DEVELOPMENT 185
16.11 CEPHEID 186
16.11.1 COMPANY SNAPSHOT 186
16.11.2 REVENUE ANALYSIS 186
16.11.3 PRODUCT PORTFOLIO 187
16.11.4 RECENT DEVELOPMENT 187
16.12 EXACT SCIENCES CORPORATION 188
16.12.1 COMPANY SNAPSHOT 188
16.12.2 REVENUE ANALYSIS 188
16.12.3 COMPANY SHARE ANALYSIS 189
16.12.4 PRODUCT PORTFOLIO 189
16.12.5 RECENT DEVELOPMENTS 190
16.13 FUJIFILM CORPORATION 191
16.13.1 COMPANY SNAPSHOT 191
16.13.2 REVENUE ANALYSIS 191
16.13.3 PRODUCT PORTFOLIO 192
16.13.4 RECENT DEVELOPMENT 192
16.14 GENERAL ELECTRIC 193
16.14.1 COMPANY SNAPSHOT 193
16.14.2 REVENUE ANALYSIS 193
16.14.3 PRODUCT PORTFOLIO 194
16.14.4 RECENT DEVELOPMENTS 194
16.15 ILLUMINA, INC. 195
16.15.1 COMPANY SNAPSHOT 195
16.15.2 REVENUE ANALYSIS 195
16.15.3 PRODUCT PORTFOLIO 196
16.15.4 RECENT DEVELOPMENTS 196
16.16 MYRIAD GENETICS, INC. 197
16.16.1 COMPANY SNAPSHOT 197
16.16.2 REVENUE ANALYSIS 197
16.16.3 PRODUCT PORTFOLIO 198
16.16.4 RECENT DEVELOPMENT 198
16.17 NANOSTRING. 199
16.17.1 COMPANY SNAPSHOT 199
16.17.2 REVENUE ANALYSIS 199
16.17.3 PRODUCT PORTFOLIO 200
16.17.4 RECENT DEVELOPMENT 200
16.17.5 RECENT DEVELOPMENT 200
16.18 ONCOSTEM. 201
16.18.1 COMPANY SNAPSHOT 201
16.18.2 PRODUCT PORTFOLIO 201
16.18.3 RECENT DEVELOPMENT 201
16.19 PROVISTA DIAGNOSTICS. 202
16.19.1 COMPANY SNAPSHOT 202
16.19.2 PRODUCT PORTFOLIO 202
16.19.3 RECENT DEVELOPMENT 202
16.20 THERMO FISHER SCIENTIFIC INC. 203
16.20.1 COMPANY SNAPSHOT 203
16.20.2 REVENUE ANALYSIS 203
16.20.3 PRODUCT PORTFOLIO 204
16.20.4 RECENT DEVELOPMENT 204
17 QUESTIONNAIRE 205
18 RELATED REPORTS 208

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.